Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial

Catherine Goujon, MDCorrespondence information about the author MD Catherine GoujonEmail the author MD Catherine Goujon

, 

Manuelle Viguier, MD, PhD

, 

Delphine Staumont-Sallé, MD, PhD

, 

Claire Bernier, MD

, 

Gérard Guillet, MD, PhD

, 

Morad Lahfa, MD

, 

Marie-Christine Ferrier Le Bouedec, MD

, 

Frédéric Cambazard, MD, PhD

, 

David Bottigioli, BA

, 

Sophie Grande, MD

, 

Karima Dahel, MD

, 

Frédéric Bérard, MD, PhD

, 

Muriel Rabilloud, MD, PhD

, 

Catherine Mercier, PhD

, 

Jean-François Nicolas, MD, PhD

PlumX Metrics

DOI: http://dx.doi.org/10.1016/j.jaip.2017.07.007

Article Info

• Abstract

• Full Text
• Images
• References

Background

Methotrexate is currently used to treat atopic dermatitis but has never been assessed versus cyclosporine in adults.

Objective

This study evaluated the efficacy and safety of methotrexate versus cyclosporine in patients with moderate-to-severe atopic dermatitis.

Methods

Patients were randomized to receive either oral methotrexate (15 mg/wk) or cyclosporine (2.5 mg/kg/d) for 8 weeks. The primary end point was a patient achieving 50% improvement in the SCORing Atopic Dermatitis index (SCORAD 50) at week 8. When the primary end point was not achieved, methotrexate was increased to 25 mg and cyclosporine to 5 mg during the next 16 weeks. The secondary end points were a patient achieving a 50% reduction in the Eczema Area Severity Intensity index (EASI 50) and SCORAD 50 at each visit (ClinicalTrials.gov no. NCT00809172).

Results

A total of 97 patients received methotrexate 15 mg (n = 50) or cyclosporine 2.5 mg (n = 47). Regarding the primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm. The difference in percentages for the 2 treatment groups (2-sided 90% CI) was −34% (−48% to −20%). At week 8, methotrexate and cyclosporine dosages were increased in 56% and 49% of the patients, respectively. Regarding EASI 50, the noninferiority end point was reached at week 20 in 92% (22 of 24) of patients in the methotrexate arm and 87% (26 of 30) of patients in the cyclosporine arm. The treatment-related adverse events were more frequent with cyclosporine (P < .0001).

Conclusions

Methotrexate 15 mg/wk was inferior to cyclosporine 2.5 mg/kg/d at week 8. Increasing the doses of methotrexate to 25 mg/wk induced a significant improvement versus cyclosporine at week 20.

Download PDF